SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING for SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Medicare/Medicaid MMM

Nuclear medicine reimbursement generally and under HOPPS and MPFS specifically. Imaging provisions of physician payment reform legislation amending the sustainable growth rate (HR 4302, the Protecting Access to Medicare Act of 2014).

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; SENATE; Nuclear Regulatory Commission (NRC)

Bills named: H.R. 4302 (113th)

Budget/Appropriations BUD

FY15 Energy/Water Appropriations (HR 83, FY2015 Omnibus Appropriations bill) regarding the DOE funding opportunities for nuclear medicine research. Funding for the National Nuclear Chemistry Summer Schools. FY15 Labor/HHS/Education appropriations regarding National Institute of Biomedical Imaging and Bioengineering funding opportunities for nuclear medicine research.

Contacted: Nuclear Regulatory Commission (NRC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 83 (113th)

Pharmacy PHA

Pharmacy compounding of radiopharmaceuticals; The Drug Quality and Security Act (HR 3204).

Contacted: Nuclear Regulatory Commission (NRC); SENATE; Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3204 (113th)

Energy/Nuclear ENG

Domestic isotope supply issues, including oversight of the American Medical Isotope Production Act of 2011. Medical radiation issues generally, including Nuclear Regulatory Commission regulations.

Contacted: Office of Science & Technology Policy (OSTP); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Nuclear Regulatory Commission (NRC); Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

21st Century Cures Initiative generally; and the creation of a new drug approval pathway at the FDA specifically.

Contacted: Nuclear Regulatory Commission (NRC); SENATE; Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)